Selected positions
2022–Present
Chief Scientific Officer
RedHill BioPharma, Ltd.
2020–Present
Board of Directors
EnGeneIC, Ltd.
2013–Present
CEO, Levitt Oncology Associates, Ltd.
Hashmonaim, Israel
2009–2013
Head, Oncology — Global Business Development
Teva Pharmaceuticals Industries, Ltd.
2006–2009
Clinical Oncology Platform Leader, Innovative R&D
Teva Pharmaceuticals Industries, Ltd.
1999–2006
Professor (Adjunct)
Dept. of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh
1997–1998
Associate Professor
Allegheny University of the Health Sciences
1987–1994
Assistant Professor · Director, Lung Cancer Center
University of Pittsburgh / Pittsburgh Cancer Institute
Selected commercial highlights
2011
Led oncology due diligence — Teva acquisition of Cephalon
Deal value: $6.8 billion
2009
Led licensing deal — OncoGeneX OGX-011 (Custirsen)
Deal value: $430M in upfront and milestone payments
2006
INO-1001 PARP inhibitor development — licensed to Genentech
Deal value: up to $625M
Selected publications
Winthrop KL et al. (incl. Levitt ML). Opaganib in COVID-19 pneumonia: Results of a randomized, placebo-controlled Phase 2a trial. Open Forum Infectious Diseases, 2022.
Horn L, Bernardo P, Levitt M et al. A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiotherapy for limited stage small cell cancer (E2596). J Thorac Oncol, 2009.
Kundel Y, Levitt ML et al. Adjuvant radiotherapy for thymic epithelial tumor. Am J Clin Oncol, 2007.
Levitt ML et al. Phase I Study of Gemcitabine Given Weekly as a Short Infusion for Non-Small Cell Lung Cancer. Lung Cancer, 2004.
Lokshin A and Levitt ML. Effect of Suramin on Squamous Differentiation and Apoptosis in Non-Small Cell Lung Cancer. J Cell Biochem, 1996.
Nair S, Mayotte J and Levitt ML. Induction of Squamous Differentiation by Interferon-β in a Human Non-Small Cell Lung Cancer Cell Line. J Natl Cancer Inst, 1994.
Takahashi T, (incl. Levitt ML). p53: A Frequent Target for Genetic Abnormalities in Lung Cancer. Science, 1989.
+ 30 additional peer-reviewed publications. Full list available in downloadable CV.
Patents
Tenne G, Levitt ML, Karapetian A. Method For The Early Diagnosis Of Cancer. Era-Massis. US20030044881, Mar 6, 2003.
Tenne G, Levitt ML, Karapetian A. Method For The Early Diagnosis Of Cancer. Era-Massis. US7449340, Nov 11, 2008.
Fathi R, Levitt M, Plasse T, Abramson D. Use of WX-UK1 and its prodrug WX-671 for the treatment of inflammatory diseases. RedHill Provisional #62/535,376, Filed: October 19, 2017.
Fathi R, Levitt M, Plasse T, Abramson D. Use of WX-UK1 and its prodrug WX-671 for the treatment of non-cancerous medical conditions. RedHill Provisional #16/034,815, Filed: July 13, 2018.
Ben-Asher D, Fathi R, Levitt M, Barnett O. Sphingosine Kinase 2 Inhibitor for Treating Coronavirus Infection in Moderately Severe Patients with Pneumonia. RedHill US Patent No. 11,471,448.
Ben-Asher D, Fathi R, Levitt M, Barnett O. Biomarkers of Coronavirus Pneumonia. RedHill US Patent No. 17/900,235, Filed: August 31, 2022.
Fathi R, Raday G, Goldberg G, Levitt M. Composition and Methods of Treating Sulfur Mustard Toxicity. RedHill US Patent No. 63/560,106, Filed: March 1, 2024.
Fathi R, Raday G, Levitt M, Goldberg G. Composition and Methods of Treating Gastrointestinal Acute Radiation Syndrome. RedHill US Patent No. 63/754,874, Filed: February 6, 2025.
Fathi R, Raday G, Levitt M. Combination Therapies and Methods of Treating Prostate Cancer. Attorney Docket No. 132471-02200/PRO, Filed US PTO.